From Launch to Leadership: Mounjaro Crosses Rs 333 Crore, Becomes India's Top-Selling Drug Written By Farhat Nasim8 Nov 2025 5:06 PM ISTNew Delhi: Eli Lilly's diabetes and obesity drug Mounjaro (Tirzepatide) has become India's top-selling drug by value for October 2025, overtaking...
Eli Lilly's Diabetes Drug Mounjaro Gets Second Brand Yurpeak via Cipla Deal Written By Farhat Nasim24 Oct 2025 11:36 AM ISTNew Delhi: In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) and Cipla...
Rs 233 Crore in 6 Months: Mounjaro Becomes India's Second-Biggest Drug by Sales Written By Farhat Nasim10 Oct 2025 3:46 PM ISTNew Delhi: In a remarkable rise, Eli Lilly's Mounjaro (tirzepatide) has become India's second-highest selling drug by value within just six months of...
Gates Foundation, PAHO Push to Make Mounjaro, Wegovy Affordable in Low-Income Countries Written By MD Bureau10 Oct 2025 3:15 PM ISTNew Delhi: The Gates Foundation and the Pan American Health Organization are both working on ways to make weight-loss drugs like Novo Nordisk's Wegovy...
Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial Written By Professor Carel W. le Roux3 Oct 2025 12:09 PM ISTSURMOUNT-5 was a 72-week, Phase 3b, multicenter, randomized, open-label, comparator-controlled study that evaluated the efficacy and safety of...
Novo Nordisk Launches Wegovy in South Africa, Ramping Up Obesity Drug Battle with Eli Lilly Farhat Nasim15 Aug 2025 3:14 PM ISTJohannesberg: Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and...
Mounjaro, Wegovy sales in India double on month in July Ruchika Sharma9 Aug 2025 1:00 PM ISTHyderabad: Sales of weight-loss drugs Wegovy by Danish pharmaceutical giant Novo Nordisk and Mounjaro by U.S.-based Eli Lilly doubled in India in...
Much Awaited Cardiac Safety Data of Tirzepatide Released Dr. Kamal Kant Kohli4 Aug 2025 8:15 AM ISTTopline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile comparable to dulaglutide...
Tirzepatide Matches dulaglutide in Heart Protection, Offers Added Benefits in SURPASS-CVOT trial Dr. Kamal Kant Kohli1 Aug 2025 9:15 AM ISTTopline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to dulaglutide in adults with...
Cipla eyes India's weight management space as demand soars: MD Umang Vohra Written By Ruchika Sharma14 July 2025 12:30 PM ISTMumbai: Mumbai-based pharma giant Cipla is gearing up to make an entry into India's rapidly growing weight management market, according to Umang...
Tirzepatide Shakes Up Obesity Market as Mounjaro Records Rs 390 Mn Sales in June Farhat Nasim11 July 2025 3:05 PM ISTNew Delhi: In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is quickly...
Delhi HC Flags Off-Label Use of Diabetes Drugs for Weight Loss, Seeks CDSCO Report Farhat Nasim3 July 2025 9:27 PM ISTNew Delhi: The Delhi High Court has directed the Central Drugs Standard Control Organisation (CDSCO) and the Drug Controller General of India (DCGI)...
